AZD-5069 is a potent and selective small molecule antagonist of the CXCR2 chemokine receptor, exhibiting an IC50 of 0.79 nM. It has been utilized in preclinical research to investigate the role of CXCR2 in inflammatory diseases, including studies in models of COPD, asthma, and cancer.